Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04559763 · ClinicalTrials.gov registry record

SpO2 Accuracy Validation of the OxySoft Sensor Via Reference CO-Oximetry Motion Study

A clinical trial of Hypoxia and Desaturation of Blood, sponsored by Medtronic - MITG.

Completed
Registry status
16
Enrollment target
1
Study location

NCT04559763 is a study of Hypoxia and Desaturation of Blood that has completed, run by Medtronic - MITG. The registered enrollment target is 16 participants, below the 3,116-participant average among 39 other Hypoxia trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04559763, a study of Hypoxia and Desaturation of Blood, has completed, sponsored by Medtronic - MITG.

COMPLETED
Registry status
16 participants
Enrollment target
1
Study location

Study Summary

SpO2 (oxygen saturation) and pulse rate accuracy of pulse oximetry equipment, OxySoft Sensor/N-600x and OxySoft Sensor/N-395, continuous measure of arterial oxygen saturation during hypoxic state throughout motion and non-motion conditions under one system configuration. The purpose of this Non-Randomized, Prospective,Observational study is to conduct a hypoxia study to directly compare a prototype OxySoft pulse oximeter system to arterial oxygen saturation.

Interventions

  • DEVICE Non-Invasive Controlled Hypoxia
  • OTHER Introduction of Motion conditions: tapping or rubbing

Study Locations (1)

Colorado

  • Clinimark - Louisville

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2020-08-18
Est. Completion 2020-08-21

Sponsor

Medtronic - MITG

119 total trials

What the Registry Record Tells You About NCT04559763

The ClinicalTrials.gov registry entry for NCT04559763 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,116-participant average among 39 other Hypoxia trials with a reported enrollment target (99% lower). The listed sponsor is Medtronic - MITG, which has 119 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hypoxia appearing as the primary indexed condition, and to 2 interventions - of which Non-Invasive Controlled Hypoxia is the first listed.

NCT04559763 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT04559763 about?

NCT04559763 is a clinical study titled "SpO2 Accuracy Validation of the OxySoft Sensor Via Reference CO-Oximetry Motion Study". SpO2 (oxygen saturation) and pulse rate accuracy of pulse oximetry equipment, OxySoft Sensor/N-600x and OxySoft Sensor/N-395, continuous measure of arterial oxygen saturation during hypoxic state throughout motion and non-motion conditions under one system configuration. The purpose of this Non-Ran...

What is the current status of trial NCT04559763?

This trial is currently completed. The enrollment target is 16 participants. The study started on 2020-08-18. Estimated completion is 2020-08-21.

What conditions does trial NCT04559763 study?

This clinical trial studies the following conditions: Hypoxia, Desaturation of Blood.

What interventions are being tested in trial NCT04559763?

The interventions under investigation include: Non-Invasive Controlled Hypoxia (DEVICE), Introduction of Motion conditions: tapping or rubbing (OTHER).

Who is sponsoring clinical trial NCT04559763?

This trial is sponsored by Medtronic - MITG, which has 119 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04559763 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypoxia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.